Management Change/Compensation - Form 8-K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 7, 2024, the Board of Directors of Pulmatrix, Inc. (the "Company") approved the termination of the Company's Chief Medical Officer ("CMO"), Dr. Margaret Wasilewski's, employment with the Company. The termination of the employment of the Company's CMO is in connection with the elimination of the position within the Company so as to transition to an outsourced, part-time CMO model, and is not in connection with any disagreement regarding any matter relating to the Company's operations, policies or practices.

Severance payments, any approved but unpaid bonus and health insurance premiums will be paid to Dr. Wasilewski pursuant to the terms of the employment letter, dated January 27, 2022, by and between the Company and Dr. Wasilewski, as amended.